RCKT ROCKET PHARMACEUTICALS INC Expansion Plans 8-K Filing 2025 - Product Expansion Rocket Pharmaceuticals, Inc. presented updates on its Phase 1 clinical trial of RP-A601 for treating plakophilin-2 related arrhythmogenic cardiomyopathy on May 15, 2025, during the ASGCT Annual Meeting. A press release detailing this data was also issued on the same date.Get access to all SEC 8-K filings of the ROCKET PHARMACEUTICALS INC